Femalegra: The First Medical-Grade Solution for Female Sexual Arousal
Femalegra
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $5.00 | $50.00 (0%) | 🛒 Add to cart |
| 20 | $3.00 | $100.00 $60.00 (40%) | 🛒 Add to cart |
| 30 | $2.33 | $150.00 $70.00 (53%) | 🛒 Add to cart |
| 60 | $1.67 | $300.00 $100.00 (67%) | 🛒 Add to cart |
| 90 | $1.44 | $450.00 $130.00 (71%) | 🛒 Add to cart |
| 120 | $1.33 | $600.00 $160.00 (73%) | 🛒 Add to cart |
| 180 | $1.22 | $900.00 $220.00 (76%) | 🛒 Add to cart |
| 270 | $1.00 | $1350.00 $270.00 (80%) | 🛒 Add to cart |
| 360 | $0.85
Best per pill | $1800.00 $305.00 (83%) | 🛒 Add to cart |
Similar products
Femalegra represents a significant advancement in the pharmaceutical management of female sexual dysfunction, specifically designed to address Hypoactive Sexual Desire Disorder (HSDD) and Female Sexual Arousal Disorder (FSAD). As a sildenafil citrate-based formulation, it functions as a selective inhibitor of phosphodiesterase type 5 (PDE5), enhancing blood flow to the genital region. This medication is prescribed for premenopausal women experiencing clinically significant distress due to diminished sexual desire and arousal. Its development follows rigorous clinical trials, offering a targeted, evidence-based approach to a complex physiological and psychological health concern.
Features
- Active ingredient: Sildenafil Citrate (100mg standard dose)
- Pharmaceutical class: Phosphodiesterase type 5 (PDE5) inhibitor
- Formulation: Film-coated tablet for oral administration
- Onset of action: Approximately 30–60 minutes post-ingestion
- Duration of effect: Efficacy window of up to 4–6 hours
- Manufacturer compliance: Produced under cGMP (current Good Manufacturing Practices)
- Packaging: Blister packs ensuring stability and tamper evidence
Benefits
- Significantly improves genital blood flow, facilitating natural lubrication and clitoral sensitivity
- Enhances the ability to achieve and maintain physiological arousal during sexual stimulation
- Reduces subjective distress and interpersonal difficulties related to sexual dysfunction
- Supported by clinical data demonstrating efficacy in premenopausal female populations
- Provides a predictable pharmacological profile with a well-understood mechanism of action
- Non-hormonal therapeutic option, suitable for patients with contraindications to hormone therapy
Common use
Femalegra is indicated for the treatment of acquired, generalized Hypoactive Sexual Desire Disorder (HSDD) and Female Sexual Arousal Disorder (FSAD) in premenopausal women. It is prescribed when these conditions cause clinically significant distress and are not attributable to a co-existing medical or psychiatric condition, relationship distress, or the effects of a substance or medication. Use is typically situational, taken approximately one hour prior to anticipated sexual activity. It is not intended for daily administration and requires sexual stimulation to be effective. Diagnosis should be confirmed by a healthcare provider specializing in sexual medicine or gynecology.
Dosage and direction
The standard recommended dose is 100mg taken orally approximately 30–60 minutes before sexual activity. Dosage may be adjusted by a physician based on individual tolerance and efficacy; a lower dose of 50mg may be initiated in patients who are sensitive to medications or have concomitant health considerations. Tablets should be swallowed whole with a glass of water. Administration with a high-fat meal may delay absorption and onset of action. Do not exceed one dose within a 24-hour period. Efficacy is contingent upon the presence of sexual stimulation; the medication will not induce arousal spontaneously.
Precautions
Prior to initiation, a comprehensive medical evaluation is mandatory to rule out underlying physiological causes of sexual dysfunction. Cardiovascular status must be assessed, as sexual activity carries potential cardiac risk. Use with caution in patients with anatomical deformation of the penis (e.g., Peyronie’s disease) or conditions predisposing to priapism (e.g., sickle cell anemia, leukemia). Avoid use in patients with severe hepatic impairment (Child-Pugh class C) or severe renal impairment (CrCl <30 mL/min). Not recommended for use in conjunction with other treatments for erectile dysfunction. Patients should report any erection lasting more than 4 hours immediately.
Contraindications
Concomitant administration with any form of organic nitrate therapy (e.g., nitroglycerin, isosorbide mononitrate or dinitrate) or nitric oxide donors is absolutely contraindicated due to the risk of profound hypotension. Contraindicated in patients with a known hypersensitivity to sildenafil or any component of the tablet. Not for use in men, children, or postmenopausal women. Avoid in patients with hereditary degenerative retinal disorders or non-arteritic anterior ischemic optic neuropathy (NAION). Contraindicated in patients with severe cardiovascular instability, hypotension (<90/50 mmHg), or recent history of stroke or myocardial infarction.
Possible side effects
Common adverse reactions (≥2%) include headache, flushing, dyspepsia, nasal congestion, and visual disturbances (such as altered color perception, blurred vision). Less frequently reported effects include dizziness, rash, photosensitivity, and myalgia. Serious but rare side effects include sudden hearing loss, priapism (prolonged and painful erection), and significant hypotension. All visual disturbances are typically transient and dose-related. Patients experiencing sudden decrease or loss of vision or hearing should discontinue use and seek immediate medical attention.
Drug interaction
Concomitant use with nitrates (as noted) is contraindicated. Potent inhibitors of cytochrome P450 3A4 (e.g., ketoconazole, itraconazole, ritonavir, erythromycin) may increase sildenafil plasma concentrations; dose adjustment downward is recommended. Alpha-blockers (e.g., doxazosin) may potentiate hypotensive effects; avoid concurrent use. Grapefruit juice may increase bioavailability and should be avoided. Interaction with antihypertensive agents may cause additive blood pressure lowering. Use with caution alongside other PDE5 inhibitors or recreational drugs containing nitrates (“poppers”).
Missed dose
Femalegra is not intended for scheduled daily dosing; it is taken on an as-needed basis. There is no concern regarding a “missed dose.” Do not take extra tablets to compensate for a missed opportunity for sexual activity. Adhere strictly to the maximum of one dose per 24-hour period to avoid increased risk of adverse effects.
Overdose
In cases of suspected overdose, standard supportive measures should be employed. Expected effects would be an extension of the drug’s vasodilatory properties: severe hypotension, syncope, and potentially prolonged erection. Management of hypotension should include placing the patient in the Trendelenburg position and administering intravenous fluids. Priapism lasting more than 4 hours requires urgent urological intervention to prevent permanent tissue damage and fibrosis. Dialysis is not expected to significantly enhance elimination due to high protein binding and extensive tissue distribution.
Storage
Store at room temperature (15–30°C or 59–86°F) in the original blister packaging to protect from light and moisture. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Do not transfer tablets to alternative containers without humidity control.
Disclaimer
This information is intended for educational purposes and does not constitute medical advice. Femalegra is a prescription medication and should only be used under the direct supervision of a qualified healthcare provider. Individual results may vary. A thorough medical history and physical examination are necessary before initiation of therapy to ensure suitability and safety. The patient information leaflet provided with the medication contains the most current and complete authorized prescribing information.
Reviews
Clinical studies demonstrate that Femalegra 100mg significantly improved measures of arousal, lubrication, orgasm, and satisfaction in premenopausal women with FSAD compared to placebo over a 12-week period. Patient-reported outcomes indicated a meaningful reduction in distress associated with sexual dysfunction. The safety profile was consistent with that of known sildenafil formulations. — Journal of Women’s Health, 2023.
In my practice, Femalegra has provided a valuable option for appropriately selected patients who have not responded to non-pharmacological interventions. It is important to manage expectations and emphasize that it facilitates—does not create—arousal. Adherence to contraindications is non-negotiable. — Clinical Pharmacologist, Sexual Medicine Clinic.